2706, 2022
Monthly focus on regulatory status of new targeted therapies in oncology – May 2022
EMA May 23. Pembrolizumab – TNBC. The European Commission approved [...]
2005, 2022
Monthly focus on regulatory status of new targeted therapies in oncology – April 2022
EMA April 1. Abemaciclib - BC HR+/HER2-. EMA has approved [...]
1204, 2022
Monthly focus on regulatory status of new targeted therapies in oncology- March 2022
CHMP March 24 – pembrolizumab – CRC/EC/BTC/SBA/GC MSI-H and CC [...]
1204, 2022
ALK rearrangements: a biomarker at the forefront of NSCLC treatment
On January 28, the European Commission approved lorlatinib as monotherapy [...]
1703, 2022
Shooting Cancer- Highlights Monthly focus on regulatory status of new targeted therapies in oncology February 2022
EMA February 18 - tepotinib - NSCLC METex14: EMA has [...]
2302, 2022
Monthly focus on regulatory status of new targeted therapies in oncology- January 2022
EMA January 9 - sotorasib-NSCLC KRAS G12C: the European Commission [...]
2601, 2022
Monthly focus on regulatory status of new targeted therapies in oncology- December 2021
CHMP December 16 - lorlatinib - NSCLC ALK fusions: EMA's [...]
2112, 2021
Shooting Cancer – Highlights Monthly focus on regulatory status of new targeted therapies in oncology – November 2021
CHMP 11 November- Sotorasib-NSCLC KRAS G12C: The EMA's Committee for [...]